NRF2 — Nuclear Factor Erythroid 2-Related Factor 2

NRF2 — Nuclear Factor Erythroid 2-Related Factor 2

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">NRF2 — Nuclear Factor Erythroid 2-Related Factor 2</th>
</tr>
<tr> [@chen2024]
<td class="label">Protein Name</td> [@cuadrado2019]
<td><strong>NRF2</strong></td> [@pajares2016]
</tr> [@dinkovakostova2015]
<tr> [@uniprot]
<td class="label">Gene</td> [@allen]
<td>[NFE2L2](/entities/nfe2l2)</td> [@allena]
</tr> [@allenb]
<tr> [@allenc]
<td class="label">UniProt</td> [@brainspan]
<td><a href="https://www.uniprot.org/uniprot/Q16236" target="_blank">Q16236</a></td> [@genes]
</tr> [@mechanisms]
<tr> [@proteins]
<td class="label">PDB</td> [@hsp]
<td><a href="https://www.rcsb.org/structure/2FLU" target="_blank">2FLU</a>, <a href="https://www.rcsb.org/structure/3WN7" target="_blank">3WN7</a></td> [@psqstm]
</tr> [@parkin]
<tr> [@pinkprotein]
<td class="label">Molecular Weight</td> [@sodprotein]
<td>~68 kDa (605 amino acids)</td> [@ref]
</tr> [@flu]
<tr> [@httpswwwncbinlmnihgovgene]
<td class="label">Subcellular Localization</td>
<td>Cytoplasm → Nucleus (upon activation)</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Cap'n'Collar (CNC) bZIP transcription factor</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">ATHEROSCLEROSIS</a>, <a href="/w

NRF2 — Nuclear Factor Erythroid 2-Related Factor 2

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">NRF2 — Nuclear Factor Erythroid 2-Related Factor 2</th>
</tr>
<tr> [@chen2024]
<td class="label">Protein Name</td> [@cuadrado2019]
<td><strong>NRF2</strong></td> [@pajares2016]
</tr> [@dinkovakostova2015]
<tr> [@uniprot]
<td class="label">Gene</td> [@allen]
<td>[NFE2L2](/entities/nfe2l2)</td> [@allena]
</tr> [@allenb]
<tr> [@allenc]
<td class="label">UniProt</td> [@brainspan]
<td><a href="https://www.uniprot.org/uniprot/Q16236" target="_blank">Q16236</a></td> [@genes]
</tr> [@mechanisms]
<tr> [@proteins]
<td class="label">PDB</td> [@hsp]
<td><a href="https://www.rcsb.org/structure/2FLU" target="_blank">2FLU</a>, <a href="https://www.rcsb.org/structure/3WN7" target="_blank">3WN7</a></td> [@psqstm]
</tr> [@parkin]
<tr> [@pinkprotein]
<td class="label">Molecular Weight</td> [@sodprotein]
<td>~68 kDa (605 amino acids)</td> [@ref]
</tr> [@flu]
<tr> [@httpswwwncbinlmnihgovgene]
<td class="label">Subcellular Localization</td>
<td>Cytoplasm → Nucleus (upon activation)</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Cap'n'Collar (CNC) bZIP transcription factor</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">ATHEROSCLEROSIS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">2185 edges</a></td>
</tr>
</table>

NRF2 — Nuclear Factor Erythroid 2-Related Factor 2

Introduction

Nrf2 (Nuclear Factor Erythroid 2 Related Factor 2) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Pathway / Mechanism Diagram

Overview

NRF2 (Nuclear factor erythroid 2-related factor 2), encoded by the NFE2L2 gene on chromosome 2q31.2, is the master transcriptional regulator of the cellular antioxidant and cytoprotective response. NRF2 orchestrates the expression of over 250 genes containing antioxidant response elements (AREs) in their promoters, encoding a broad battery of phase II detoxification enzymes, antioxidant proteins, and anti-inflammatory mediators [@nrf2020][@contribution2021]. Under basal conditions, NRF2 is kept at low levels through ubiquitin-proteasome degradation mediated by its negative regulator Keap1 (Kelch-like ECH-associated protein 1). Upon [oxidative-stress](/mechanisms/oxidative-stress), electrophilic signals, or therapeutic activators, NRF2 dissociates from Keap1, translocates to the nucleus, and drives transcription of cytoprotective genes [@nrf2020].

NRF2 dysfunction has been implicated in virtually all major neurodegenerative diseases, including [alzheimers](/diseases/alzheimers-disease), [parkinsons](/diseases/parkinsons-disease), [als](/diseases/als), [huntington-pathway](/mechanisms/huntington-pathway), and [multiple-sclerosis](/diseases/multiple-sclerosis). In these conditions, NRF2 activity declines with aging and disease
progression, leaving [neurons](/entities/neurons) and glia increasingly vulnerable to [oxidative-stress](/mechanisms/oxidative-stress), [mitochondrial-dysfunction](/mechanisms/mitochondrial-dysfunction), and [neuroinflammation](/mechanisms/neuroinflammation)
[@contribution2021][@reinforcing2025]. Pharmacological NRF2 activators — including dimethyl fumarate (Tecfidera), already FDA-approved for MS — represent
one of the most promising therapeutic strategies for neuroprotection across multiple neurodegenerative diseases [@nrf2020][@reinforcing2025].

Structure

NRF2 is a 605-amino-acid Cap'n'Collar (CNC) basic leucine zipper (bZIP) transcription factor with seven functional Neh (Nrf2-ECH homology) domains:

• Neh1: Contains the CNC-bZIP domain for DNA binding and dimerization with small Maf proteins; mediates binding to ARE sequences (5′-TGACnnnGC-3′) in target gene promoters [@nrf2020].
• Neh2: N-terminal regulatory domain containing DLG and ETGE motifs that interact with Keap1 for ubiquitin-dependent degradation. The "hinge and latch" model describes how the high-affinity ETGE and low-affinity DLG motifs bind Keap1 [@nrf2020].
• Neh3: C-terminal transactivation domain; interacts with the chromo-ATPase/helicase DNA-binding domain (CHD6).
• Neh4 and Neh5: Transactivation domains that recruit CBP/p300 coactivators.
• Neh6: Serine-rich domain; mediates Keap1-independent degradation through β-TrCP/[gsk3-beta](/mechanisms/gsk3-beta) phosphorylation.
• Neh7: Interacts with retinoic X receptor α (RXRα) to repress NRF2 activity.

Normal Function

Keap1-NRF2-ARE Signaling Pathway

The canonical NRF2 activation pathway operates as a cellular stress sensor [@nrf2020][@contribution2021]:

Key NRF2 Target Genes

NRF2 drives expression of a comprehensive cytoprotective program [@contribution2021][@targeting2024]:

| Category | Target Genes | Function |
|----------|-------------|----------|
| Antioxidant enzymes | HO-1, NQO1, SOD, catalase, GPx | Neutralize [reactive oxygen species](/entities/reactive-oxygen-species) |
| Glutathione synthesis | GCLC, GCLM, GSS, GSR | Rate-limiting enzymes for glutathione biosynthesis |
| Thioredoxin system | TXN, TXNRD1 | Reduce oxidized proteins |
| Phase II detoxification | GSTs, UGTs | Conjugate and detoxify xenobiotics |
| Proteasome subunits | PSMB5, PSMA1 | Enhance protein quality control |
| Anti-inflammatory | IL-1β suppression, HMOX1 | Reduce [neuroinflammation](/mechanisms/neuroinflammation) |
| Iron metabolism | Ferritin H/L, ferroportin | Prevent [ferroptosis](/mechanisms/ferroptosis) |
| Mitophagy | PINK1, p62/SQSTM1 | Promote [mitophagy](/mechanisms/mitophagy) of damaged mitochondria |

Role in Disease

Alzheimer's Disease

NRF2 activity is reduced in the [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex) of AD patients, with nuclear NRF2 levels decreasing as disease severity increases
[@contribution2021][@reinforcing2025]:

• [Amyloid-Beta](/proteins/amyloid-beta) oligomers generate [oxidative-stress](/mechanisms/oxidative-stress) that initially activates NRF2, but chronic exposure overwhelms the pathway, leading to NRF2 exhaustion
• Hyperphosphorylated [tau](/proteins/tau)[/proteins/[tau-protein](/proteins/tau) disrupts NRF2 nuclear import, further compromising antioxidant defenses [@reinforcing2025]
• NRF2 knockout mice show exacerbated amyloid pathology, [neuroinflammation](/mechanisms/neuroinflammation), and cognitive deficits
• NRF2 activation (by sulforaphane, DMF, or genetic overexpression) ameliorates AD pathology in transgenic mouse models [@contribution2021][@nrf2020]

Parkinson's Disease

• Loss of [dopaminergic-neurons-snpc](/cell-types/dopaminergic-neurons-snpc) in the [substantia-nigra](/brain-regions/substantia-nigra) is associated with high oxidative burden and diminished NRF2 signaling [@contribution2021]
• [alpha-synuclein](/proteins/alpha-synuclein) aggregates impair NRF2 function by sequestering p62/SQSTM1, disrupting selective [autophagy](/entities/autophagy) [@contribution2021]
• NRF2 activators protect dopaminergic [neurons](/entities/neurons) in MPTP, 6-OHDA, and rotenone PD models [@nrf2020]
• [pink1-protein](/proteins/pink1-protein) and [parkin](/proteins/parkin)-mediated [mitophagy](/mechanisms/mitophagy) is positively regulated by NRF2 through p62 induction

ALS

• [sod1-protein](/proteins/sod1-protein) mutant mice show progressive decline in NRF2 activity in spinal cord [motor-neurons](/cell-types/motor-neurons)
• NRF2 activation delays disease onset and extends survival in SOD1-G93A mice [@nrf2020]
• [tdp-43](/proteins/tdp-43) proteinopathy impairs NRF2-mediated stress response in motor [neurons](/entities/neurons)

Huntington's Disease

• Mutant [huntingtin](/proteins/huntingtin) protein disrupts NRF2-dependent gene expression in striatal [medium-spiny-neurons](/cell-types/medium-spiny-neurons)
• NRF2 activation reduces mutant [huntingtin](/proteins/huntingtin) aggregation and improves motor function in HD models [@contribution2021]

Therapeutic Targeting

NRF2 activation is a highly active area of therapeutic development for neurodegeneration [@nrf2020][@reinforcing2025]:

Approved NRF2 Activators

• Dimethyl fumarate (DMF / Tecfidera): FDA-approved for [multiple-sclerosis](/diseases/multiple-sclerosis). Activates NRF2 by modifying Keap1 cysteine residues. Reduces neuroinflammation, enhances glutathione levels, and protects oligodendrocytes. Under investigation for AD and PD [@nrf2020][@reinforcing2025].
• Omaveloxolone (Skyclarys): FDA-approved for [friedreichs-ataxia](/diseases/friedreichs-ataxia) (2023). The first NRF2 activator approved specifically for a neurodegenerative condition. Synthetic triterpenoid that potently activates NRF2 [@reinforcing2025].

Investigational NRF2 Activators

• Sulforaphane: Natural isothiocyanate from cruciferous vegetables; potent NRF2 activator; clinical trials in autism, AD, and schizophrenia
• Curcumin analogs: Modified curcuminoids with improved bioavailability; NRF2 activators in preclinical studies
• CDDO derivatives: Synthetic triterpenoids with NRF2-activating properties; clinical trials for various indications

Brain Atlas Resources

• Allen Human Brain Atlas: [NRF2 expression search](https://human.brain-map.org/microarray/search/show?search_term=NRF2)
• Allen Mouse Brain Atlas: [NRF2 search](https://mouse.brain-map.org/search/index.html?query=NRF2)
• Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
• BrainSpan Developmental Transcriptome: [NRF2 developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=NRF2)

See Also

• [Index

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

Background

The study of Nrf2 (Nuclear Factor Erythroid 2 Related Factor 2) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: LOX/LOXL1-4

Pathway Diagram

The following diagram shows the key molecular relationships involving NRF2 — Nuclear Factor Erythroid 2-Related Factor 2 discovered through SciDEX knowledge graph analysis: